Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.

Cancer - 1 May 2018

Xuan Li, Wang Yu, Huang Fen, Jiang Erlie, Deng Lan, Wu Bingyi, Fan Zhiping, Liang Xinquan, Xu Na, Ye Jieyu, Lin Ren, Yin Changxin, Zhang Yuanyuan, Sun Jing, Han Mingzhe, Huang Xiaojun, Liu Qifa

Abstract excerpt

BACKGROUND: The objective of this study was to evaluate the effect of sorafenib on the outcomes of patients with acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: A total of 144 patients with FLT3-ITD AML undergoing allo-HSCT between January 2012 and December 2015 were enrolled...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Combined Modality Therapy
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gain of Function Mutation

Share to Remission Induction

Share to Segmental Duplications, Genomic

Share to Sorafenib

Share to Tandem Repeat Sequences

Share to Transplantation, Homologous

Source

Identifiers

PMID: 29509276
DOI: 10.1002/cncr.31295

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.PMID 29509276Read ↗

[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].Semantic proximity Read ↗

Characteristics and Outcome of FLT3-ITD-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].Semantic proximity Read ↗

Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.Semantic proximity Read ↗

Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.Semantic proximity Read ↗

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).Semantic proximity Read ↗

Post-transplant sorafenib effectively prevents relapse in FLT3-mutated acute myeloid leukemia.Semantic proximity Read ↗

[Efficacy and safety of Sorafenib as monotherapy to FLT3-ITD positive acute myeloid leukemia].Semantic proximity Read ↗

[Sorafenib in combination with chemotherapy as first-line therapy for FLT3-ITD positive acute myeloid leukemia].Semantic proximity Read ↗

FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.Semantic proximity Read ↗

Prognosis and outcome of patients with acute myeloid leukemia based on FLT3‑ITD mutation with or without additional abnormal cytogeneticsSemantic proximity Read ↗

[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.